Section Arrow
Quote
SGMT.NASDAQ
- Sagimet Biosciences Inc. - Series A
Quotes are at least 15-min delayed:2026/06/07 03:36 EDT
Regular Hours
Last
 6.76
-0.3 (-4.25%)
Day High 
7.11 
Prev. Close
7.06 
1-M High
8.38 
Volume 
608.35K 
Bid
6.65
Ask
7.28
Day Low
6.73 
Open
7.03 
1-M Low
6.43 
Market Cap 
435.97M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 7.1 
20-SMA 7.17 
50-SMA 6.61 
52-W High 11.41 
52-W Low 4.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.35/-0.99
Enterprise Value
435.97M
Balance Sheet
Book Value Per Share
1.66
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BCDABioCardia Inc.1.03+0.111+12.08%-- 
BGMSBio Green Med Solution Inc1.5+0.44+41.51%0.3PE
CMNDClearmind Medicine Inc.3.98+1.07+36.77%-- 
ADTXAditxt Inc.0.0621-0.0149-19.35%-- 
RXRXRecursion Pharmaceuticals3.315-0.485-12.76%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.